Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + Carboplatin + Docetaxel in Early Stage TNBC
NCT07017673Phase 2Recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in triple-negative breast cancer (TNBC), sponsored by Cedars-Sinai Medical Center. Started Jul 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07017673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07017673.